Abdallah S, Agbamu D, Aurangabadkar A, Carser J, Helliwell T, Husband D, et al. 2014, Guidelines for the investigation and management of metastatic malignant disease of unknown primary origin (V 1.2). NHS Cheshire & Merseyside Strategic Clinical Networks.

Australian Cancer Network Adult Brain Tumour Guidelines Working Party 2009, Clinical practice guidelines for the management of adult gliomas: astrocytomas and oligodendrogliomas. Cancer Council Australia, Australian Cancer Network and Clinical Oncological Society of Australia Inc., Sydney.

Australian Commission on Safety and Quality in Health Care (ACSQHC) 2004, Standard for credentialing and defining the scope of clinical practice, ACSQHC, Sydney.

Australian Commission on Safety and Quality in Health Care (ACSQHC) 2011, National Safety and Quality Health Service Standards, ACSQHC, Sydney, viewed March 2015, <http://www.safetyandquality.gov.au/wp- content/uploads/2011/09/NSQHS-Standards- Sept-2012.pdf>.

Australian Commission on Safety and Quality in Health Care (ACSQHC) 2013, Consumers, the health system and health literacy: taking action to improve safety and quality, Consultation Paper, ACSQHC, Sydney.

Australian Health Ministers’ Advisory Council (AHMAC) 2011, A national framework for advance care directives, AHMAC, Canberra, viewed November 2017, <http://www.coaghealthcouncil.gov.au/ Portals/0/A%20National%20Framework%20 for%20Advance%20Care%20Directives_ September%202011.pdf>.

Australian Institute of Health and Welfare (AIHW) 2014, Cancer in Australia: an overview 2014, Cancer series No. 90. Cat. no. CAN 88, AIHW, Canberra.

Australian Institute of Health and Welfare (AIHW) 2018, Cancer compendium: information and trends by cancer type; Cancer of unknown primary site in Australia, AIHW, Canberra.

Berner A, Davidson B, Sigstad E, Risberg B 2003, ‘Fine-needle aspiration cytology vs core biopsy in the diagnosis of breast lesions.’ Diagn Cytopathol 29(6): 344–348.

Boyland L, Davis C 2008, ‘Patients’ experiences of carcinoma of unknown primary site: dealing with uncertainty.’ Palliat Med 22(2): 177–183.

Brandes K, Linn AJ, Butow PN, van Weert JC 2014, ‘The characteristics and effectiveness of Question Prompt List interventions

in oncology: a systematic review of the literature.’ Psychooncology, viewed September 2014, <http://www.ncbi.nlm.nih.gov/ pubmed/25082386>.

Brewster DH, Lang J, Bhatti LA, Thomson CS, Oien KA 2014, ‘Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961–2010.’ Cancer Epidemiol 38(3): 227–234.

Burglin SA, Hess S, Høilund-Carlsen PF, Gerke O 2017, ‘18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: a systematic review and meta-analysis.’ Medicine (Baltimore) 96(16): e6713.

Cancer Australia 2010, Complementary and alternative therapies, Cancer Australia, Surry Hills, NSW, viewed October 2013, <https:// canceraustralia.gov.au/publications-and- resources/position-statements/complementary- and-alternative-therapies>.

Cancer Australia 2015, National Aboriginal and Torres Strait Islander cancer framework, Cancer Australia, Surry Hills, NSW, viewed April 2018, <https://canceraustralia.gov.au/sites/default/ files/publications/national-aboriginal-and-torres- strait-islander-cancer-framework/pdf/2015_atsi_ framework_1.pdf>.

Cancer Council Australia 2017, Cancer of unknown primary, viewed October 2017,

<http://www.cancer.org.au/about-cancer/types- of-cancer/cancer-of-unknown-primary.html>.

Clinical Oncology Society of Australia (COSA) 2011, Psychosocial management of AYAs diagnosed with cancer: guidance for health professionals, COSA, Sydney, viewed January 2012, <http://wiki.cancer.org.au/australia/COSA:Psychosocial_management_of_AYA_ cancer_patients>.

Clinical Oncology Society of Australia (COSA) 2013, Annual Scientific Meeting and Workshop.

Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, et al.; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) 2003, ‘Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study – trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).’ J Clin Oncol 21(18): 3479–3482.

Department of Health 2007a, Achieving best practice cancer care: a guide for implementing multidisciplinary care, State Government of Victoria, Melbourne.

Department of Health 2007b, Linking cancer care: a guide for implementing coordinated cancer care, State Government of Victoria, Melbourne.

Department of Health 2009, Cultural responsiveness framework: Guidelines for Victorian health service.

Ferrari A, Thomas D, Franklin A, Hayes-Lattin B , Mascarin M, van der Graaf W, et al. 2010, ‘Starting an adolescent and young adult program: some success stories and some obstacles to overcome.’ J Clin Oncol, 28(32): 4850–4857.

Fitch M 2000, ‘Supportive care for cancer patients.’ Hosp Q 3(4): 39–46.

Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G 2015, ‘Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow- up.’ Ann Oncol 26 (suppl_5): v133–v138.

Gatalica Z, Millis SZ, Vranic S, Bender R, Basu GD, Voss A, et al. 2014, ‘Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.’ Oncotarget 5(23): 12440–12447.

Greco A 2013, ‘Cancer of unknown primary site: improved patient management with molecular and immunohistochemical diagnosis.’ ASCO Meeting Library, viewed October 2017,

<https://meetinglibrary.asco.org/record/78842/ edbook#fulltext>.

Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, et al. 2016, ‘Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.’ Cold Spring Harb Mol Case Stud 2(6): a001180.

Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, et al. 2012, ‘Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.’ Eur J Cancer 48(5): 721–727.

Haines IE 2011, ‘Managing patients with advanced cancer: the benefits of early referral for palliative care.’ Med J Aust 194(3): 107–108.

Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS, Farley C, et al. 2010, ‘Paclitaxel/ carboplatin/etoposide versus gemcitabine/ irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.’ Cancer J 16(1): 70–75.

Hewitt M, Greenfield S, Stovall E 2006, From cancer patient to cancer survivor: lost in transition, National Academies Press, Washington.

Higginson IJ, Evans CJ 2010, ‘What is the evidence that palliative care teams improve outcomes for cancer patients and their families?’ Cancer J 16(5): 423–435.

Hudson P, Trauer T, Kelly B, O’Connor M, Thomas K, Zordan R, et al. 2014, ‘Reducing the psychological distress of family caregivers of home based palliative care patients: longer term effects from a randomised controlled trial.’ Psycho-Oncology, 24(1): 19–24.

Hyphantis T, Papadimitriou I, Petrakis D, Fountzilas G, Repana D, Assimakopoulos K, et al. 2013, ‘Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site.’ Psychooncology 22(9): 2009–2015.

Janssen S, Glanzmann C, Huber G, Studer G 2014, ‘Individualized IMRT treatment approach for cervical lymph node metastases of unknown primary.’ Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 190(4): 386–393.

Kaaks R, Sookthai D, Hemminki K, Kramer A, Boeing H, Wirfalt E, et al. 2014, ‘Risk factors for cancers of unknown primary site: results from the prospective EPIC cohort.’ Int J Cancer 135(10): 2475–2481.

Karapetis CS, Guccione L, Tattersall MH, Gooden H, Vajdic CM, Lambert S, et al. 2017, ‘Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologists.’ Intern Med J 47(4): 408–414.

Lang V, Walter S, Fessler J, Koester MJ, Ruetters D, Huebner J 2017, ‘The role of the general practitioner in cancer care: a survey of the patients’ perspective.’ J Cancer Res Clin Oncol 143(5): 895–904.

Losa F, Soler G, Casado A, Estival A, Fernández I, Giménez S, et al. 2018, ‘SEOM clinical guideline on unknown primary cancer.’ Clin Transl Oncol 20(1): 89–96.

Luke C, Koczwara B, Karapetis C, Pittman K, Price T, Kotasek D, et al. 2008, ‘Exploring

the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care.’ Aust N Z J Public Health 32(4): 383–389.

National Breast Cancer Centre (NBCC), National Cancer Control Initiative (NCCI) 2003, Clinical practice guidelines for the psychosocial care of adults with cancer, NBCC, Camperdown.

National Cancer Institute (NCI), US Department of Health and Human Services (USDHHS) 2006, Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000, National Cancer Institute, National Institutes of Health, Bethesda, MD.

National Cancer Survivorship Initiative (NCSI) 2015, Stratified pathways of care, NHS England.

National Comprehensive Cancer Guidelines (NCCN) 2017, Occult primary (cancer of unknown primary [CUP]), Version 2.2017 – October 17, 2016.

National Institute for Clinical Excellence (NICE) 2004, Guidance on cancer service – improving supportive and palliative care for adults with cancer, NICE, London, UK, viewed October 2013, <http://guidance.nice.org.uk/CSGSP>.

National Institute for Health and Care Excellence (NICE) 2010, Diagnosis and management

of metastatic malignant disease of unknown primary origin, viewed November 2017, <https://www.nice.org.uk/guidance/cg104/evidence/full-guideline-pdf-134697133>.

Palliative Care Australia 2005, Standards for providing quality palliative care for all Australians (4th edition), Palliative Care Australia, Deakin.

Park SY, Kim BH, Kim JH, Lee S, Kang GH 2007, ‘Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.’ Arch Pathol Lab Med 131(10): 1561–1567.

Pavlidis N, Fizazi K 2005, ‘Cancer of unknown primary (CUP).’ Crit Rev Oncol Hematol 54(3): 243–250.

Pavlidis N, Pentheroudakis G 2012, ‘Cancer of unknown primary site.’ Lancet 379(9824): 1428–1435.

Pavlidis N, Khaled H, Gaafar R 2015, ‘A mini review on cancer of unknown primary site: a clinical puzzle for the oncologists.’ J Adv Res 6(3): 375–382.

Peppercorn J, Weeks J, Cook F, Joffe S 2004, ‘Comparison of outcomes in cancer patients treated within and outside cli0.nical trials: conceptual framework and structured review.’ Lancet 363: 263–270.

Philip J, Collins A, Brand C, Moore G, Lethborg C, Sundararajan V, Murphy M, Gold M, 2013, ‘“I’m just waiting…”: an exploration of the experience of living and dying with primary malignant glioma’, Support Care Cancer, Springer-Verlag Berlin, Melbourne.

Pitkethly M, Macgillivray S, Ryan R 2008, ‘Recordings or summaries of consultations for people with cancer.’ Cochrane Database Syst Rev 2008(3): Cd001539.

Rich SE, Mendenhall WM 2016, ‘Short- course radiation for palliation of squamous cell carcinoma of an unknown primary of the head and neck.’ J Clin Oncol 34(26) (October): 62–62.

Riihimaki M, Thomsen H, Hemminki A, Sundquist K, Hemminki K 2013a, ‘Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.’ BMC Cancer 13: 36.

Riihimaki M, Hemminki A, Sundquist K, Hemminki K 2013b, ‘Time trends in survival from cancer of unknown primary: small steps forward.’ Eur J Cancer 49(10): 2403–2410.

Robotin MC, George J, Supramaniam R, Sitas F, Penman A 2008, ‘Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy?’ Med J Aust 188(6): 363–365.

Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. 2015, ‘Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies.’ JAMA Oncol 1(1): 40–49.

Schaffer AL, Pearson SA, Dobbins TA, Er CC, Ward RL, Vajdic CM 2015, ‘Patterns of care and survival after a cancer of unknown primary (CUP) diagnosis: a population-based nested cohort study in Australian Government Department of Veterans’ Affairs clients.’ Cancer Epidemiol 39(4): 578–584.

Silver JK, Baima J 2013, ‘Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes.’ Am J Phys Med Rehabil 92(8): 715–727.

Sjoquist K, Zalcberg J 2013, ‘Clinical trials – advancing cancer care.’ Cancer Forum 37(1), viewed October 2012, <www.cancerforum.org. au/Issues/2013/March/Forum/ Clinical_trials. htm>.

Smith A, Bellizzi K, Keegan T, Zebrack B, Chen V, Neale A, et al. 2013, ‘Health-related quality of life of adolescent and young adult patients with cancer in the United States: the Adolescent and Young Adult Health Outcomes and Patient Experience Study.’ J Clin Oncol 31(17): 2136– 2145.

Steer B, Marx G, Singhal N, McJannett M, Goldstein D, Prowse R 2009, ‘Cancer in older people: a tale of two disciplines.’ Intern Med J 39: 771–775.

Taillibert S, Laigle-Donadey F, Sanson M 2004, ‘Palliative care in patients with primary brain tumours’, Current Opinion in Oncology, vol. 16, pp. 587–592.

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA 2010, ‘Early palliative care for patients with non-metastatic nonsmall cell lung cancer.’ New Engl J Med 363(8): 733–742.

Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, et al. 2017, ‘Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial.’ J Clin Oncol 35(8): 834–841.

Tey J, Soon YY, Koh WY, Leong CN, Choo BA, Ho F, et al. 2017, ‘Palliative radiotherapy for gastric cancer: a systematic review and meta- analysis.’ Oncotarget 8(15): 25797–25805.

Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, et al. 2013, ‘Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.’ J Pathol 231(4): 413–423.

Urban D, Rao A, Bressel M, Lawrence YR, Mileshkin L 2013, ‘Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities.’ Br J Cancer 109(5): 1318–1324.

Varghese AM, Arora A, Capanu M, Camacho N, Won HH, Zehir A, et al. 2017, ‘Clinical and molecular characterization of patients with cancers of unknown primary in the modern era.’ Ann Oncol 28(12): 3015–3021.

Vajdic CM, Goldstein D 2015, ‘Cancer of unknown primary site.’ Aust Fam Physician 44(9): 640–643.

Wagland R, Bracher M, Drosdowsky A, Richardson A, Symons J, Mileshkin L, et al. 2017, ‘Differences in experiences of care between patients diagnosed with metastatic cancer of known and unknown primaries: mixed-method findings from the 2013 cancer patient experience survey in England.’ BMJ Open 7(9): e017881.

Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighly N, Oza A, et al. 2014, ‘Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial.’ Lancet 383(9930): 1721–1730.